

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)



(10) International Publication Number
WO 2021/195557 A3

(51) International Patent Classification:

A61K 35/12 (2015.01) A61K 39/00 (2006.01)
A61K 35/17 (2015.01) A61K 39/39 (2006.01)
A61K 35/26 (2015.01)

(21) International Application Number:

PCT/US2021/024473

(22) International Filing Date:

26 March 2021 (26.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/001,011 27 March 2020 (27.03.2020) US

(71) Applicants: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th St., Austin, TX 78701 (US). **ASYLIA THERAPEUTICS** [US/US]; 2450 Holcombe Blvd, Suite J, Houston, TX 77021 (US).

(72) Inventors: **ORLOWSKI, Robert Z.**; c/o The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (US). **JONES, Richard, J.**; c/o The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (US). **BOVER, Laura, C.**; c/o The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 (US). **GYURIS, Jenő**; c/o Asyilia Therapeutics, 2450 Holcombe

Blvd, Suite J., Houston, TX 77021 (US). **MILLER, John**; c/o Asyilia Therapeutics, 2450 Holcombe Blvd, Suite J., Houston, TX 77021 (US).

(74) Agent: **SCHNEPP, Amanda, S.J.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MONOCLONAL ANTIBODIES TARGETING HSP70 AND THERAPEUTIC USES THEREOF




FIG. 1

(57) Abstract: Provided herein are agents, such as antibodies and chimeric antigen receptors, that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.

[Continued on next page]

WO 2021/195557 A3

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:

04 November 2021 (04.11.2021)